Oncol Lett 19: [Related article:] 992-1000, 2020; DOI:
10.3892/ol.2019.11135
Following the publication of the above paper, an
interested reader drew to the authors’ attention that there were
inconsistencies in the description of the results shown in Fig. 2B, comparing between the Results and
the Discussion sections.
Upon investigating this matter with the authors, the
authors have realized that the description of the results
concerning this experiment was correct in the Discussion, but was
wrong in the Results section (and elsewhere). First, Fig. 2B was labelled incorrectly, and the
corrected version of Fig. 2 is shown
oppossite. Otherwise, the text relating to this Figure should have
been written as follows (changes are highlighted in bold):
(i) Abstract, p. 992, line 21: “Low tissue
miR-769-3p expression predicted poor overall survival in patients
with glioma (log-rank P=0.001)”;
(ii) Results section, p, 994, Prognostic value of
tissue miR-769-3p level in patients with glioma subsection,
line 4: “The results demonstrated that patients with a low
miR-769-3p expression in the glioma tissue exhibited relatively
poor overall survival compared with those in the high expression
group (log-rank P=0.001; Fig.
2B).”
(iii) Fig. 2B legend,
p. 996: “(B) Patients with low miR-769-3p expression
exhibited shorter survival times compared with those with
high miR-769-3p expression.”
The authors are grateful to the Editor of
Oncology Letters for allowing them the opportunity to
publish this Corrigendum; furthermore, the authors apologize for
any inconvenience caused to the readership of the Journal.
